AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen...
VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.